Figure 6

Dose–response effect of MR309 treatment on spinal cord injury (SCI)-induced mechanical allodynia and thermal hyperalgesia in wild type (WT) mice. Analgesic effects on (A,C) mechanical allodynia and (B,D) thermal hyperalgesia of the sigma-1 receptor antagonist MR309 (S1RA) 30 min after administration at 28 days after SCI. Each bar and vertical line represents the mean ± standard error of the mean (n = 4–7 per group). a–c: groups not sharing a letter are significantly different, p < 0.05. MR309 treatment dose-dependently reversed both mechanical and thermal hypersensitivity.